Welcome to SFA Therapeutics

A New Paradigm in Drug Development

About Us

SFA Therapeutics, LLC is a development-stage bio-pharmaceutical startup company focused on a new advancement in the treatment of chronic inflammatory disease-- the use of microbiome-derived metabolites as drugs

A completely new approach to drug discovery and development

Deriving drugs from bacterial metabolites found in man means no genotoxicity, faster clinical development and safer treatments

Our pipeline includes treatments for Psoriasis, Liver Cancer (Hepatitis B, NASH and HCC), Ophthalmic Diseases, Cytokine Release Syndrome- a side effect in CAR-T, Prevention of Relapse/Recurrence in Leukemias, and other diseases.

Safer, Faster to Market and Lower R&D Cost

Our microbiome-derived drugs are derived from natural substances, and enable a new platform for developing treatments which have the potential to treat over 85 chronic inflammatory diseases currently afflicting patients; providing safer treatments than current therapies.

Our proprietary discovery process matches metabolites and adjuvants to treat specific indications caused by chronic inflammation. This approach results in much faster drug development and much faster clinical development, with higher probabilities for success.

Current Focus

Pipeline

Our first drug is an oral treatment for psoriasis

• Oral drug (tablet or capsule)

• Enteric-coated

• Extended release

• Twice per day dosing (potential for once daily)

• Low side-effect profile; not an MAB, no antibodies

• Low cost of goods

• Can be combined with marketed drugs to lower side effects and increase overall efficacy

Summary of the Psoriasis Market Landscape

• Current treatments are expensive

• Follow-up healthcare burden, testing and follow-up cost is high

• Co-morbidity is high (potential to treat with the same SFA drug)

• Efficacy is not always sustained; patients often need to switch therapies

• Patient, prescriber and payer satisfaction is low

• “Patients are afraid to try current treatments”- themarket is underserved

SFA’s drug addresses major unmet needs in the psoriasismarket

Data:

In a small case-controlled human trial, a Proof of Activity treatment effect was observed.

A Phase 2A Proof of Concept trial is planned for 2018-2019.

Our second drug candidate is focused on Hepatitis B, NASH and Hepatocellular Carcinoma

Data:

In-vitro data demonstrated a significant reduction in both the number of hepatocellular carcinoma tumors and in tumor sizes, in HBX mice.